Detection and incidence of muscular adverse drug reactions: A prospective analysis from laboratory signals

European Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2004, Pages 285-292

  Dugue A ^a   Bagheri, H ^a   Lapeyre Mestre, M ^a   Tournamille, J F ^a   Sailler, L ^b   Dedieu, G ^b   Salvayre, R ^c   Thouvenot, J P ^b   Massip, P ^d   Montastruc, J L ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CHU PURPAN   (France)

^c CHU RANGUEIL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Drug induced muscular injuries; Laboratory monitoring; Rhabdomyolysis

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIRETROVIRUS AGENT; CERIVASTATIN; CREATINE KINASE; FIBRIC ACID DERIVATIVE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

AUTOANALYSIS; CREATINE KINASE BLOOD LEVEL; DATA ANALYSIS; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FRANCE; HUMAN; MEDICAL RECORD; MUSCLE CONTRACTURE; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

ADULT; AGED; CREATINE KINASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; RHABDOMYOLYSIS;

EID: 3142724146     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Daniel P, Pratt O (1977) The metabolic homeostatic role of muscle and its function as a store of protein. Lancet 27:446-448
2. Poels PJ, Gabreels FJ (1993) Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 95:175-192
3. Dayer-Berenson L (1994) Rhabdomyolysis: a comprehensive guide. ANNA 121:15-18
4. Charatan F (2001) Bayer decides to withdraw cholesterol-lowering drug. BMJ 323:359
5. Begaud B (2000) Critères d'imputabilité des accidents d'origine médicamenteuse. Rev Prat 50:1803-1806
6. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255-1259
7. Anonymous (2003) Dictionnaire VIDAL, 79th edn. O.V.P., Paris
8. Tubert P, Bégaud B, Péré JEA (992) Power and weakness of spontaneous reporting: a probabilistic approach. J Clin Epidemiol 45:283-286
9. Haramburu F (1993) Estimation of under-reporting. Methodological approaches in pharmacoepidemiology: application to spontaneous reporting ARME-P. Elsevier Science Publishers, Amsterdam, pp 39-49
10. Thürmann P (2001) Methods and systems to detect adverse drug reactions in hospitals. Drug Saf 24:961-968
11. Azaz-Livshits T, Levy M (1998) Computerized surveillance of adverse drug reactions in hospital: a pilot study. Br J Clin Pharmacol 45:309-314
12. Tegeder I, Levy M, Muth-Selbach U (1999) Retrospective analysis of the frequency and recognition of adverse reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 47:557-564
13. Bagheri H, Michel F, Lapeyre-Mestre M et al (2000) Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 50:479-484
14. Levy M, Azaz-Livshits T, Sadan B et al (1999) Computerized surveillance of adverse reactions in hospital: implementation. Eur J Clin Pharmacol 54:887-892
15. Salame G, Péré JC, Chaslerie A et al (1990) Liver injuries: a prospective study (abstract). J Clin Res Pharmacoepidemiol 4:133
16. Blanco JR, Zabalza M, Salcedo J et al (2002) Rhabdomyolysis of infectious and non-infectious causes. South Med J 95:542-544
17. Gabow P, Kaehny W (1982) The spectrum of rhabdomyolysis. Medicine 61:141-152
18. Phillips PS, Haas RH, Bannykh S et al (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585
19. Wortmann RL (2002) Lipid-lowering agents and myopathy. Curr Opin Rheumatol 14:643-647
20. Thompson PD, Clarkson P, Richard H (2003) Statin-associated myopathy. JAMA 289:1681-1690
21. Evans M, Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25:649-663
22. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al (2002) ACC/ AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 106:1024-1028
23. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096-1107
24. Ucar M, Mjorndal T, Dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22:441-457
25. Bannwarth B (2002) Drug-induced myopathies. Expert Opin Drug Saf 1:65-70
26. http://www.agmed.sante.gouv.fr/htm/10/statine Muscular risk of statins. Cited June 4th, 2002
27. Gaist D, Alberto Garcia Rodriguez L, Huerta C et al (2000) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12:565-569
28. Le Quintrec JS, Le Quintrec JL (1991) Drug-induced myopathies. Bailleres Clin Rheumatol 5:21-38
29. Serratrice G, Desnuelle C, Cros D (1984) Les atteintes musculaires d'origine médicamenteuse. Thérapie 39:677-687
30. Sieb JP, Gillessen T (2003) Iatrogenic and toxic myopathies. Muscle Nerve 27:142-156
31. Zuckner J (1990) Drug-induced myopathies. Semin Arthritis Rheum 19:259-268
32. Jeroen J, Toine CG (2002) Incidence and determinants of CK and liver function measurements in patients using statins. Pharmacoepidemiol Drug Saf 11:875
33. Paoletti R, Corsini A, Bellosta S (2002) Pharmacological interactions of statins. Atheroscler Suppl 3:35-40
34. Mora C, Rodriguez ML, Navarro JF (2001) Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin. Transplantation 72:551
35. Dalakas M, Illa I, Pezeshkpour G et al (1990) Mitochondrial myopathy caused by long term zidovudine therapy. N Engl J Med 322:1098-1105
36. Lui W (1979) Phenothiazine-induced dystonia associated with an increase in serum creatine phosphokinase. Arch Dis Child 54:150-151
37. Egan MF, Dargham AA, Kirch DG, Wyatt RJ (1993) Serum creatine phosphokinase elevations in patients with tardive dyskinesia. Br J Psychiatry 162:551-553
38. Northoff G, Wenke J, Pflug B (1996) Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 26:547-553
39. Avina-Zubieta J, Johnson E, Suarez-Almazor M, Russel A (1995) Incidence of myopathy in patients treated with anti-malarials. A report of three cases and a review of the literature. Br J Rheumatol 34:166-170
40. Cacoub P, Sbai A, Azizi P et al (1999) Polymyositis induced by tiopronin. Presse Med 28:911-912